Karuna Therapeutics

Karuna Therapeutics company information, Employees & Contact Information

Karuna Therapeutics, Inc. is now part of Bristol Myers Squibb. Learn about how we are continuing to transform the lives of patients with neurological and neuropsychiatric diseases @Bristol Myers Squibb or www.bms.com.

Company Details

Employees
63
Founded
-
Address
99 High Street, Floor 26,united States
Phone
6174823337
Email
in****@****rma.com
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
Keywords
jobs.
HQ
Boston, Massachusetts
Looking for a particular Karuna Therapeutics employee's phone or email?

Karuna Therapeutics Questions

News

Karuna Therapeutics Announces Exclusive Global License Agreement for Goldfinch Bio’s Investigational TRPC4/5 Product Candidates - Business Wire

Karuna Therapeutics Announces Exclusive Global License Agreement for Goldfinch Bio’s Investigational TRPC4/5 Product Candidates Business Wire

Karuna Therapeutics to Present at Upcoming Investor Conferences - The AI Journal

Karuna Therapeutics to Present at Upcoming Investor Conferences The AI Journal

Karuna Therapeutics - Massachusetts Biotechnology Council

Karuna Therapeutics Massachusetts Biotechnology Council

Karuna Therapeutics Announces Positive Results from Phase 3 EMERGENT-2 Trial of KarXT in Schizophrenia - Stock Titan

Karuna Therapeutics Announces Positive Results from Phase 3 EMERGENT-2 Trial of KarXT in Schizophrenia Stock Titan

Karuna Therapeutics Reports Third Quarter 2023 Financial Results and Provides General Business Updates - Business Wire

Karuna Therapeutics Reports Third Quarter 2023 Financial Results and Provides General Business Updates Business Wire

Karuna Therapeutics to Present at Upcoming Investor Conferences - FinancialContent

Karuna Therapeutics to Present at Upcoming Investor Conferences FinancialContent

Karuna Therapeutics Announces U.S. Food and Drug Administration Accepts New Drug Application for KarXT for the Treatment of Schizophrenia - Business Wire

Karuna Therapeutics Announces U.S. Food and Drug Administration Accepts New Drug Application for KarXT for the Treatment of Schizophrenia Business Wire

Karuna Therapeutics Appoints William P. Kane as Chief Commercial Officer - Business Wire

Karuna Therapeutics Appoints William P. Kane as Chief Commercial Officer Business Wire

Karuna Therapeutics Announces Pricing of Public Offering of Common Stock - Business Wire

Karuna Therapeutics Announces Pricing of Public Offering of Common Stock Business Wire

Karuna Therapeutics Announces Positive Results from Phase 3 EMERGENT-3 Trial of KarXT in Schizophrenia - Business Wire

Karuna Therapeutics Announces Positive Results from Phase 3 EMERGENT-3 Trial of KarXT in Schizophrenia Business Wire

Top Karuna Therapeutics Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant